Zydus Receives Health Canada Approval for Mesalamine Suppositories
Zydus Lifesciences Limited has received a Notice of Compliance (NOC) from Health Canada for generic Mesalamine suppositories 1000 mg.
Mesalamine suppositories are indicated for the treatment of active ulcerative proctitis.
- Zydus also received NOC from Health Canada for generic Liothyronine tablets 5 mcg and 25 mcg in October.
- Liothyronine tablets are used to treat hypothyroidism.
Zydus Lifesciences Ltd. is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Author summary: Zydus gets approval for Mesalamine suppositories.
More News
- Lakers’ Jaxson Hayes sits out against Timberwolves
- Inexcusable but not disqualifying | Kiwiblog
- Sixty-five nations sign first UN treaty to fight cybercrime, in milestone for digital cooperation
- Japan PM Takaichi Leaves for ASEAN-Related Summits in Malaysia
- As Israeli Settlers Attack Americans, When Will We Say ‘Enough’?
- Dauda Lawal: Between Leadership Award And Zamfara Reality
- Darby Allin Talks About The Possibility Of Turning Heel
- Playmakers propel Buffaloes past Patterson
- Mattingly’s Revenge Hounds Dodgers In World Series Vs. Blue Jays
- Basallo, Beavers made notable debuts for Orioles in 2025 - BaltimoreBaseball.com